logo
Share SHARE
FONT-SIZE Plus   Neg

AVI BioPharma's Eteplirsen Meets PrimaryEndpoint For Duchenne Muscular Dystrophy

AVI BioPharma Inc. (AVII), a developer of RNA-based therapeutics, reported that treatment with eteplirsen met the primary efficacy endpoint in a randomized, double-blind, placebo-controlled Phase IIb study in boys with Duchenne muscular dystrophy or DMD. Eteplirsen administered once weekly at 30mg/kg over 24 weeks resulted in a statistically significant increase in novel dystrophin compared to no increase in the placebo group.

In the study, a shorter duration of eteplirsen treatment, 12 weeks, did not show a significant increase in novel dystrophin, despite administration of the drug at a higher dose, the company added. This finding suggests that a longer duration of dosing is required before meaningful levels of dystrophin are produced.

Eteplirsen is AVI's lead drug candidate that is systemically delivered for the treatment of a substantial subgroup of patients with DMD.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Pepsi is pulling large bottles of its products from Philadelphia grocery store shelves after the city's new 1.5-cent-per-ounce tax on sweetened drinks. Its rival Coca-Cola has also been pulling its large bottles, reports said. They are being replaced with smaller bottles and cans of the drinks. Around 17,000 AT&T Inc workers in California and Nevada went on strike on Wednesday, alleging that the telecom giant violated contract terms. The employees, who work in the company's phone, landline and cable services businesses, walked out, formally known as a grievance strike, for forcing employees to do work outside their areas of expertise. Google Maps introduced a new feature to share real-time location to a contact for 15 minutes to 3 days. The feature can be turned off at any time by the user. The tech leader believes that the feature will help friends meet up in a large park or a restaurant at a new location. One can open share...
comments powered by Disqus
Follow RTT